MALVERN, Pa.–(BUSINESS WIRE)–#ASMMicrobe2019—VenatoRx
Pharmaceuticals will present ten posters featuring its two
development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145,
at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. VenatoRx
will also present an overview if its antibacterial agents portfolio
during the Pharma Pipeline Update, concentrating on its orally
bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents
Discovery Summary Session.
VenatoRx’s presentations at ASM Microbe will take place as follows:
— Friday, June 21, 2019 —
Title: Orally Bioavailable Beta-lactamase Inhibitor VNRX-7145
9:50am – 10:10am PT
Presenter: Daniel C. Pevear, Ph.D., Senior Vice
President, Biology, VenatoRx Pharmaceuticals
Location: 207/208 South
Pipeline Update: Part I
Title: VenatoRx Pipeline
Time: 3:03pm – 3:14pm PT
Christopher J. Burns, Ph.D., President and CEO, VenatoRx Pharmaceuticals
AAR Track Hub (Booth 5053) – Learn – Exhibit and Poster Hall
— Sunday, June 23, 2019 —
AAR08 – New
Antimicrobial Agents (pre-Phase 2): Early Beta-Lactams and
Beta-Lactamase Inhibitor Combinations
Poster Presentation |
11:00am – 1:00pm PT
Location: Exhibit and Poster Hall
SUNDAY – AAR-719 — Rescue of Ceftibuten Activity by the Oral
β-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing
Class A, C and/or D β-Lactamases. K.J. John, C.L. Chatwin,
J.C. Hamrick, G. Moeck, D.C. Pevear.
SUNDAY – AAR-720 — The Orally Bioavailable Beta-Lactamase
Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten
against Enterobacteriaceae Expressing Ambler Class A, C, and/or D
Enzymes. J.C. Hamrick, C.L. Chatwin, K.J. John, G. Moeck, L.
Xerri, D.C. Pevear.
SUNDAY – AAR-721 — In Vitro Activity of Ceftibuten in
Combination with VNRX-7145 and Comparators against 1,066 UTI Isolates
Non-Susceptible to Amoxicillin-Clavulanate and Levofloxacin. M.
Hackel, D. Sahm.
SUNDAY – AAR-722 — Antimicrobial Activity of Cefepime in
Combination with VNRX-5133 against a Global 2018 Surveillance
Collection of Pseudomonas aeruginosa. M. Hackel, D. Sahm.
SUNDAY – AAR-723 — Synergy/Antagonism of
Ceftibuten/VNRX-7145 in Combination with Other Commonly Used
Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic
Bacteria, and Yeast. C.L. Chatwin, K.J. John, J.C. Hamrick, C.J.
Burns, D.C. Pevear, G. Moeck.
SUNDAY – AAR-724 — In Vitro Permeability and
Metabolic Biotransformation of Oral Beta-Lactamase Inhibitor VNRX-7145
across Species. R.E. Trout, C.L. Chatwin, L. McLaughlin, J.C.
Hamrick, G. Moeck, D.C. Pevear.
SUNDAY – AAR-726 — Efficacy of Ceftibuten + VNRX-7145 a
Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a
Murine UTI Mode. M.E. Pulse, W. J. Weiss, P. Nguyen, D. Valtierra,
K. Peterson, K. Carter, G. Moeck, R.E. Trout, J. Hamrick, D.C. Pevear.
SUNDAY – AAR-727 — Assessment of the In Vivo Pharmacodynamic
Profile of Ceftibuten/VNRX-7145 Combination against Serine
β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine
Thigh Infection Model. L.M. Avery, K. Abdelraouf, D.P. Nicolau.
SUNDAY – AAR-728 — Oral Bioavailability of Novel
Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human
Primates. D. Pevear, R. Trout, L. McLaughlin, J. Hamrick, G. Moeck.
CPHM02 – Antimicrobial
Susceptibility Testing – Test Performance for New Agents
Location: Exhibit and Poster Hall
SUNDAY – CPHM-860 — Impact of Variations in Susceptibility
Testing Parameters on the In Vitro Activity of Ceftibuten in
Combination with VNRX-7145. M. Hackel, D. Dressel, D. Sahm.
About VenatoRx Pharmaceuticals
VenatoRx is a private pharmaceutical company that is focused on the
discovery and development of novel anti-infectives to treat
multi-drug-resistant bacterial infections and hard-to-treat viral
infections. Founded in 2010, VenatoRx has built a world-class in-house
R&D organization that has filed over 100 patents spanning multiple
research programs. VenatoRx has received significant funding awards from
the National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health (NIH), Wellcome Trust, CARB-X, and the
Defense Threat Reduction Agency (DTRA) as well as private equity
investments from Versant Ventures, Abingworth, and Foresite Capital.
The Company’s most advanced development-stage product is VNRX-5133, an
injectable beta-lactamase inhibitor (BLI) that features selective and
potent in vitro activity against both serine- and
metallo-beta-lactamases, including ESBL, OXA, KPC, NDM, and VIM enzymes.
VenatoRx believes that VNRX-5133, in a fixed combination with the fourth
generation cephalosporin, cefepime, has the potential to provide a
valuable broad-spectrum treatment option to meet unmet medical need in
patients with infections due to carbapenem-resistant pathogens including
carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas
aeruginosa (CRPA), suspected polymicrobial infections caused by both
gram-negative and gram-positive susceptible pathogens, and engineerable
MDR bioterror pathogens such as Burkholderia spp. and Salmonella
spp. Early clinical studies of cefepime/VNRX-5133 have been completed
and VenatoRx intends to initiate Phase 3 pivotal trials during the third
quarter 2019. This project has been funded in whole or in part with
Federal funds from the National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Department of Health and Human
Services, under Contract No. HHSN272201300019C, and The Wellcome Trust
under Award No. 360G-Wellcome-101999/Z/13/Z.
VenatoRx’s second development-stage product in clinical development is
VNRX-7145, an orally bioavailable BLI that in a fixed combination with
the third generation orally bioavailable cephalosporin, ceftibuten, has
the potential to rescue activity of the partner antibiotic against ESBLs
and key carbapenem-resistant Enterobacteriaceae, including those
expressing KPC and OXA carbapenemases. This project has been funded in
part with Federal funds from the National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Department of Health
and Human Services, under Contract No. HHSN272201600029C.
Additionally, VenatoRx has a broad pipeline of preclinical programs
including a novel class of Penicillin-Binding Protein (PBP) inhibitors
that are impervious to beta-lactamase-driven resistance, and novel
antiviral agents targeting Hepatitis B Virus. For more information,
please visit www.venatorx.com.
VenatoRx Pharmaceuticals, Inc.